They indicate that S9-A13 could potentially interact with both SLC26A9 and TP53, suggesting a possible multi-target regulatory mechanism affecting key signaling pathways and the tumor microenvironment of cancer stem cells. Here, SLC26A9 is linked to neoplasm.